Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Mar;266(3):598-608.
doi: 10.1007/s00415-018-09172-1. Epub 2019 Jan 8.

Clinical effect of successful reperfusion in patients presenting with NIHSS < 8: data from the BEYOND-SWIFT registry

Johannes Kaesmacher  1   2 , Panagiotis Chaloulos-Iakovidis  2 , Leonidas Panos  2 , Pasquale Mordasini  1 , Mirjam R Heldner  2 , Christoph C Kurmann  2 , Patrik Michel  3 , Steven D Hajdu  4 , Marc Ribo  5 , Manuel Requena  5 , Christian Maegerlein  6 , Benjamin Friedrich  6 , Vincent Costalat  7 , Amel Benali  7 , Laurent Pierot  8 , Matthias Gawlitza  8 , Joanna Schaafsma  9 , Vitor Mendes Pereira  10 , Jan Gralla  1 , Urs Fischer  11
Affiliations
Multicenter Study

Clinical effect of successful reperfusion in patients presenting with NIHSS < 8: data from the BEYOND-SWIFT registry

Johannes Kaesmacher et al. J Neurol. 2019 Mar.

Abstract

Background and purpose: If patients presenting with large vessel occlusions (LVO) and mild symptoms should be treated with endvoascular treatment (EVT) remains unclear. Aims of this study were (1) assessing the safety and technical efficacy of EVT in patients with NIHSS < 8 as opposed to a comparison group of patients presenting with NIHSS ≥ 8 and (2) evaluation of the clinical effect of reperfusion in patients with NIHSS < 8.

Methods: Patients included into the retrospective multicenter BEYOND-SWIFT registry (NCT03496064) were analyzed. Clinical effect of achieving successful reperfusion (defined as modified Thrombolysis in Cerebral Infarction grade 2b/3) in patients presenting with NIHSS < 8 (N = 193) was evaluated using multivariable logistic regression analyses (displayed as adjusted Odds Ratios, aOR and 95% confidence intervals, 95%-CI). Primary outcome was excellent functional outcome (modified Rankin Scale, mRS 0-1) at day 90. Safety and efficacy of mechanical thrombectomy in patients with NIHSS < 8 was compared to patients presenting with NIHSS ≥ 8 (N = 1423).

Results: Among patients with NIHSS < 8 (N = 193, 77/193, 39.9% receiving pre-interventional IV-tPA), successful reperfusion was significantly related to mRS 0-1 (aOR 3.217, 95%-CI 1.174-8.816) and reduced the chances of non-hemorrhagic neurological worsening (aOR 0.194, 95%-CI 0.050-0.756) after adjusting for prespecified confounders. In interaction analyses, the relative merits of achieving successful reperfusion were mostly comparable between patients presenting with NIHSS < 8 and NIHSS ≥ 8 as evidenced by non-significantly different aOR. Interventional safety and efficacy metrics were similar between patients with NIHSS < 8 and NIHSS ≥ 8.

Conclusions: Achieving successful reperfusion is beneficial in patients with persisting LVO presenting with NIHSS < 8 and reduces the risk of non-hemorrhagic neurological worsening.

Keywords: Endovascular; Low NIHSS; Mechanical thrombectomy; Mild symptoms; Stroke; Thrombolysis.

PubMed Disclaimer

Conflict of interest statement

Dr. Fischer is a consultant for Medtronic and Stryker and Co-PI of the SWIFT DIRECT trial (Medtronic). Dr Gralla is a global principal investigator of STAR (Solitaire FR Thrombectomy for Acute Revascularisation), clinical event committee member of the PROMISE study (European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke; Penumbra), and a principal investigator and consultant for the SWIFT DIRECT study (Medtronic) and receives Swiss National Science Foundation (SNSF) grants for magnetic resonance imaging in stroke. Dr Pierot serves as a consultant for Balt, Microvention, and Penumbra. Dr. Kaesmacher has received travel grants from Pfizer and Stryker and received research grants from the SAMW/Bangerter Foundation and the Swiss Stroke Society. Dr Ribo serves as a consultant for Medtronic, Stryker, Anaconda, Apta Targets, and Perflow Medical and as a speaker for Neuravi. Dr Michel has received funding for speaker honoraria from Boehringer. He has served on scientific advisory boards also for Boehringer. He has received research grants from Bristol-Myers Squibb, Boehringer, and the Swiss Heart Foundation. Dr. Pereira is a consultant for Stryker (SC for DAWN trial), Penumbra (SC for PROMISE study), BALT (proctorship of products unrelated to ischemic stroke), Phenox, Rapid Medical, Neurovasc and receives research a grant from Philips. All other authors declare that there are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Study Flow Chart of the BEYOND-SWIFT Registry
Fig. 2
Fig. 2
Day 90 Functional Outcome. a Comparison of patients with NIHSS < 8 and patients presenting with NIHSS ≥ 8; b, Patients with NIHSS < 8 dichotomized according to their reperfusion success; NIHSS National Institute of Health Stroke Scale, mRS modified Rankin Scale
Fig. 3
Fig. 3
adjusted Odds Ratios of successful reperfusion (TICI2b/3) for various endpoints with strata of admission NIHSS < 8 vs NIHSS ≥ 8. Adjusted Odds Ratios were calculated in split cohorts using multivariable binary logistic regression adjusting for all variables outlined in the methods section. Analysis was rerun implementing the variable NIHSS < 8 vs NIHSS ≥ 8 and the term NIHSS < 8 vs NIHSS ≥ 8 * TICI2b/3 (reperfusion) to test for potential interaction in the whole cohort (the variable admission NIHSS was ommitted in this model, accordingly)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Heldner MR, Zubler C, Mattle HP, et al. National institutes of health stroke scale score and vessel occlusion in 2152 patients with acute ischemic stroke. Stroke. 2013;44:1153–1157. doi: 10.1161/STROKEAHA.111.000604. - DOI - PubMed
    1. Maas MB, Furie KL, Lev MH, et al. National Institutes of Health Stroke Scale score is poorly predictive of proximal occlusion in acute cerebral ischemia. Stroke. 2009;40:2988–2993. doi: 10.1161/STROKEAHA.109.555664. - DOI - PMC - PubMed
    1. Goyal M, Menon BK, Van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723–1731. doi: 10.1016/S0140-6736(16)00163-X. - DOI - PubMed
    1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2018;49(3):e46–e110. doi: 10.1161/STR.0000000000000158. - DOI - PubMed
    1. Marks MP, Lansberg MG, Mlynash M, et al. Effect of collateral blood flow on patients undergoing endovascular therapy for acute ischemic stroke. Stroke. 2014;45:1035–1039. doi: 10.1161/STROKEAHA.113.004085. - DOI - PMC - PubMed

Publication types

Substances

Grants and funding